Skip to main content
. Author manuscript; available in PMC: 2013 Jan 6.
Published in final edited form as: J Neurosci. 2012 May 23;32(21):7278–7286. doi: 10.1523/JNEUROSCI.6273-11.2012

Figure 4. PKCε mediates Lck activation in PC.

Figure 4

A and B, Pretreatment with εV1–2 (PCKε inhibitor; 10 µM) using Bioporter abolished NMDA PC neuroprotection in PI-staining (A) or LDH leakage (B). Pharmacological activation of PKCε by ψεRACK (10 µM) demonstrated a similar effect as NMDA PC. PKCε, protein kinase C epsilon. *p<0.05 and **p<0.01 vs. NMDA lethal; #p<0.05 vs. NMDA PC+NMDA lethal. C, Co-localization of PKCε with Lck was increased by NMDA PC. Lck or PKCε in each Lck-immunoprecipitates were examined by western blot. D, Inhibition of PKCε by εV1–2 reversed NMDA PC-induced Lck kinase activation. εV1–2 (10 µM) was treated by Bioporter prior to PC, and cell lysates were collected for Lck immunoprecipitation and kinase assay. *p<0.05 vs. Control without PC; #p<0.05 vs. NMDA PC. A:n=3, B:n=3, C:n=3, D:n=3. All values are means ± SEM and analyzed by Student’s t-test.